A comparative analysis of frontier large language model (LLM) performance on standardized knowledge assessments and real world scenarios in genitourinary (GU) malignancies.

S Sameer S. Deshmukh (Mobile Infirmary, Mobile, AL) A Aaqid Syed O Oluwatayo Adeoye (1Mayo Clinic, Hematology/Oncology, Rochester, United States) F Furhan Yunus (8Infirmary Health, Mobile, United States) U Umang Swami (Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA) I Irbaz Bin Riaz (Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA) W Winston Tan N Neeraj Agarwal (Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA) G Guru P. Sonpavde (AdventHealth Cancer Institute Orlando, Orlando, FL) A Arnab Basu (Division of Hematology and Oncology, Mayo Clinic Florida, Jacksonville, FL)

Abstract

21 Background: Large language models (LLMs) are becoming an increasing source of medical information for both patients and providers. Clinical decision making is occasionally complex and may use factors outside of traditional guidelines. We conducted a comparative performance evaluation of frontier models on standardized genitourinary (GU) oncology knowledge assessments derived from the American Society of Clinical Oncology Self-Evaluation Program 2025 (ASCO SEP 2025) in addition to challenging questions developed by GU oncology experts. Methods: Three frontier LLMs were selected: ChatGPT-5.2 (OpenAI, San Francisco, CA, USA), Claude Opus 4.6 (Anthropic, San Francisco, CA, USA), and Gemini 3 Pro (Google DeepMind, Mountain View, CA, USA). Model selection was based on publicly reported performance on “Humanity’s Last Exam,” a benchmark of advanced scientific reasoning (Scale AI leaderboard Jan-Feb 2026). The OpenEvidence (OpenEvidence Inc., MA, USA) search engine was also selected for evaluation. All models were asked 145 ASCO SEP 2025 GU oncology questions and 12 real world challenging scenarios using an uniform prompt. Subject matter experts peer reviewed LLM generated responses to challenging questions and credit was given only for correct rationale and option selection. Results: All models demonstrated high and comparable accuracy on Standardized knowledge assessment, with Gemini 3 Pro leading numerically at 97.24% (95% CI, 93.1% – 99.0%), OpenEvidence followed with an accuracy of 94.48% (95% CI, 89.5% – 97.3%), while Chat GPT -5.2 and Claude OPUS 4.6 scored 92.41% (95%, CI 86.9% – 95.7%) and 79.31% (95% CI, 71.9% – 85.1%) respectively. On challenging real world scenarios, ChatGPT-5.2 demonstrated the highest numerical accuracy at 100% (95% CI, 75.8% – 100%), Gemini 3 Pro and Open Evidence scored 75.0% (95% CI, 46.8%–91.1%) each, followed by Claude Opus 4.6 at 66.7% (39.1–86.3). Conclusions: All current frontier AI models appear to provide accurate medical information and rationale on a large majority of guideline based medical knowledge assessments for GU oncology. Frontier AI models also appear to have emerging competence in highly challenging real-world scenarios. AI based tools may become a valuable and reliable tool for patients and providers. Comparative LLM performance. Model ASCO SEP 2025 % (95% CI) Real World Scenarios % (95% CI) Gemini 3 Pro 97.24% (93.1–99.0) 75.0% (46.8–91.1) OpenEvidence 94.48% (89.5–97.3) 75.0% (46.8–91.1) ChatGPT-5.2 92.41% (86.9–95.7) 100% (75.8–100) Claude Opus 4.6 79.31% (71.9–85.1) 66.67% (39.1–86.3)

Article Details

Volume / Issue Vol. 44, Issue 19_suppl
Published July 01, 2026
Pages 21-21
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (10)

S

Sameer S. Deshmukh

Mobile Infirmary, Mobile, AL

A

Aaqid Syed

O

Oluwatayo Adeoye

1Mayo Clinic, Hematology/Oncology, Rochester, United States

F

Furhan Yunus

8Infirmary Health, Mobile, United States

U

Umang Swami

Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA

I

Irbaz Bin Riaz

Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA

W

Winston Tan

N

Neeraj Agarwal

Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA

G

Guru P. Sonpavde

AdventHealth Cancer Institute Orlando, Orlando, FL

A

Arnab Basu

Division of Hematology and Oncology, Mayo Clinic Florida, Jacksonville, FL